We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.10 | -3.32% | 32.00 | 31.95 | 32.00 | 34.50 | 31.00 | 34.50 | 4,439,000 | 16:29:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 188.24 | 172.85M |
TIDMAPH
RNS Number : 1844Z
Alliance Pharma PLC
25 May 2016
For immediate release 25 May 2016
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, will hold its Annual General Meeting ("AGM") in London later this morning. At the meeting, the Company's Chairman, Andrew Smith, will make the following statement:
"The year has started well. The Alliance business and the recently acquired Sinclair Healthcare Products business together generated revenues of GBP30.5 million for the first four months of 2016, which is in line with the Board's expectations.
"Kelo-Cote(TM), our scar reduction product from the Sinclair portfolio, is now our largest-selling brand. Its sales of GBP3.0 million in the first four months of 2016 were in line with forecast. Hydromol(TM), the largest selling brand in the Alliance product range, continued to grow well with sales in the first four months of the year up 7% on the same period in the prior year. The UK consumer healthcare business also continues to develop well, with sales of GBP2.9 million up 20% on the same period last year, driven by strong growth of Ashton and Parsons(TM) and Macushield(TM), which was acquired in February 2015.
"The key activity of combining the two organisations is underway. We are in the process of integrating the Sinclair products under the Alliance name and of aligning the operational capabilities of the enlarged company; both projects are progressing to plan.
"We look forward to the year ahead with confidence."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer Sarah Robinson, Company Secretary www.alliancepharma.co.uk Buchanan + 44 (0) 20 7466 5000 Mark Court / Sophie Cowles / Jane Glover Numis Securities Limited + 44 (0) 20 7260 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMAKQDDABKDDPB
(END) Dow Jones Newswires
May 25, 2016 02:00 ET (06:00 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions